Within the southern region of the Netherlands, the Maastricht Study is an on-going observational prospective population-based cohort study that focuses on the etiology of Type 2 diabetes mellitus (T2DM). Representativeness of the participating population is a crucial but often an unknown factor in population-based cohort studies such as the Maastricht Study. We therefore aimed to assess the representativeness of the study population by comparing drug utilization of the participants of the Maastricht Study with the general population of the Netherlands.Since T2DM patients were oversampled in this study, a sampling method was applied in order to ensure a similar distribution of T2DM over the study population. Drug use in the study population was compared with drug use in the population of the Netherlands, using a Z-test to compare 2 independent proportions.In general, drug use in the study was similar compared with national data. However, in the age group 65 to 74 years total drug use was lower in the study population (833/1000 persons) versus nationwide data (882/1000 persons). The use of pulmonary medications was lower (104/1000 persons vs 141/1000 persons) and the use of hypnotics/anxiolytics was higher (90/1000 persons vs 36/1000 persons) in the Maastricht Study as compared with national data.Drug use in the Maastricht Study population is largely comparable to that in the total Dutch population aged 45 to 74. Therefore, data on drug use by participants in the Maastricht Study can be used to perform studies assessing outcomes associated with drug use.

Original languageEnglish
Article number18524
Number of pages8
Issue number1
Publication statusPublished - Jan 2020


  • Aged
  • Anti-Anxiety Agents/therapeutic use
  • Diabetes Mellitus, Type 2/drug therapy
  • Drug Utilization/statistics & numerical data
  • Female
  • Humans
  • Hypnotics and Sedatives/therapeutic use
  • Male
  • Middle Aged
  • Netherlands/epidemiology
  • Population Health/statistics & numerical data
  • Prospective Studies
  • Respiratory System Agents/therapeutic use
  • drug utilization
  • RISK
  • epidemiology
  • participation bias
  • type 2 diabetes
  • Maastricht Study

Cite this